Brachytherapy pp 137-146 | Cite as

Prostate Brachytherapy: Clinical Efficacy and Future Trends

  • Peter F. OrioIIIEmail author
  • Katelyn A. Crouse
  • Paul L. Nguyen
  • Martin T. King


Low-dose rate (LDR) prostate brachytherapy is a highly efficacious and cost-effective treatment with a very favorable side effect profile and has a role in the treatment paradigm of low-, intermediate-, and high-risk prostate cancers. Brachytherapy is typically an outpatient procedure where tiny radioactive “seeds” are implanted in the prostate to eradicate the cancer right where it has grown. Brachytherapy has a long and proven track record with data demonstrating it to be extremely effective when used alone in low and favorable intermediate-risk prostate cancer. Brachytherapy also shows significantly higher rates of cancer control and tumor eradication in the higher-risk setting when used in combination with external beam radiation therapy (EBRT) as compared to surgery or EBRT alone.

Despite its efficacy, brachytherapy utilization rates are declining secondary to competing treatment options, to include a shift to active surveillance. With prostate cancer diagnosis on the rise, and prospective and randomized trials showing brachytherapy’s superior efficacy over other modalities such as radical prostatectomy and EBRT, it is important to put corrective actions in place to ensure that brachytherapy is available to patients across the globe.


Prostate cancer Brachytherapy Low risk Intermediate risk High risk Outcomes 


  1. 1.
    Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.1, Cancer incidence and mortality worldwide: IARC CancerBase no. 11 [internet]. Lyon, France: International Agency for Research on Cancer; 2014.Google Scholar
  2. 2.
    Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD,, based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
  3. 3.
    Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate Cancer results study group. BJU Int. 2012;109(Suppl 1):22–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Bittner NH, Orio PF, Merrick GS, Prestidge BR, Hartford AC, Rosenthal SA. The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer. Brachytherapy. 2017;16(1):59–67.CrossRefPubMedGoogle Scholar
  5. 5.
    Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate Cancer in the National Cancer Data Base. Cancer. 2014;120:2114–21.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW. Prostate brachytherapy case volumes by academic and non-academic practices: implications for future residency training. Int J Radiat Oncol Biol Phys. 2016;96(3):624–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen YW. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy. 2016;15(6):701–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N. Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol. 2011;29(4):362–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys. 2011;81(1):1–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kittel JA, Reddy CA, Smith KL, Stephans KL, Tendulkar RD, Ulchaker J, Angermeier K, Campbell S, Stephenson A, Klein EA, Wilkinson DA, Ciezki JP. Long-term efficacy and toxicity of low-dose-rate 125I prostate brachytherapy as monotherapy in low-, intermediate-, and high-risk prostate Cancer. Int J Radiat Oncol Biol Phys. 2015;92(4):884–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Lo AC, Morris WJ, Pickles T, Keyes M, McKenzie M, Tyldesley S. Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients. Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):745–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327–33.CrossRefPubMedGoogle Scholar
  13. 13.
    Prestidge BR, Winter K, Sanda MG, Amin M, Bice WS, Michalski J, Ibbott GS, Crook JM, Catton CN, Gay HA, Donavanik V, Beyer DC, Frank SJ, Papagikos MA, Rosenthal SA, Barthold HJ, Sandler HM RM. Initial report of NRG oncology/RTOG 0232: a phase III study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic carcinoma. Int J Radiat Oncol Biol Phys. 2016;96(2):S4.CrossRefGoogle Scholar
  14. 14.
    Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):804–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate Cancer. Cancer. 2011;117(24):5579–88.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Morris WJ, Tyldesley S, Roda S, Halperon R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiation Oncol Biol Phys. 98:275–85.Google Scholar
  17. 17.
    Dibiase SJ, Hussain A, Kataria R, Amin P, Bassi S, Dawson N, Kwok Y. Long-term results of a prospective, phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):732–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Pfeiffer D, Sutlief S, Feng W, Pierce HM, Kofler J. AAPM task group 128: quality assurance tests for prostate brachytherapy ultrasound systems. Med Phys. 2008 Dec;35(12):5471–89.CrossRefPubMedGoogle Scholar
  19. 19.
    Thaker NG, Kudchadker RJ, Swanson DA, Albert JM, Mahmood U, Pugh TJ, Boehling NS, Bruno TL, Prestidge BR, Crook JM, Cox BW, Potters L, Moran BJ, Keyes M, Kuban DA, SJ F. Establishing high-quality prostate brachytherapy using a phantom simulator training program. Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):579–86.CrossRefPubMedGoogle Scholar
  20. 20.
    Mariados NM, Sylverseter J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiation Oncol Biol Phys. 2014;92(5):971–7.CrossRefGoogle Scholar
  21. 21.
    Hamstra DA, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiation Oncol Biol Phys. 2017;97(5):976–85.CrossRefGoogle Scholar
  22. 22.
    Pugh TJ, Pokharel SS. Magnetic resonance imaging in prostate brachytherapy: evidence, clinical end points to data, and direction forward. Brachytherapy. 2017;16:659–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Thaker NG, Pugh TJ, Mahmood U, Choi S, Spinks TE, Martin NE, Sio TT, Kudchadker RJ, Kaplan RS, Kuban DA, Swanson DA, Orio PF, Zelefsky MJ, Cox BW, Potters L, Buchholz TA, Feeley TW, Frank SJ. Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy. 2016 May-Jun;15(3):274–82.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Orio PF, Durkee B, Lanni T, Lievens Y, Petereit D. Is brachytherapy cost effective? In: William Y, Tanderup K, Pieters B, editors. Emerging Technologies in Brachytherapy. Boca Raton: CRC Press; 2017.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Peter F. OrioIII
    • 1
    Email author
  • Katelyn A. Crouse
    • 2
  • Paul L. Nguyen
    • 1
  • Martin T. King
    • 1
  1. 1.Dana-Farber/Brigham and Women’s Cancer CenterHarvard Medical SchoolBostonUSA
  2. 2.Dana-Farber/Brigham and Women’s Cancer CenterBostonUSA

Personalised recommendations